Pembrolizumab plus lenvatinib with belzutifan or quavonlimab as first-line therapy for advanced renal-cell carcinoma: randomized open-label phase 3 LITESPARK-012 study

By afschroeder • October 26, 2026

Rini BI, Choueiri TK, Voss MH, Burotto M, Oldenburg J, Gurney HP, Ferguson TR, Hammers H, Albiges L, Ürün Y, Romero Diaz RI, Özgüroğlu M, Weber PY, Verzoni E, Porta C, Drakaki A, Guo J, Matsubara N, Chen A, Burgents JE, Rodriguez-Lopez KG, Powles TB. Pembrolizumab plus lenvatinib with belzutifan or quavonlimab as first-line therapy for advanced renal-cell carcinoma: randomized open-label phase 3 LITESPARK-012 study. Ann Oncol. 2026 Oct 25:S0923-7534(26)08071-3. doi: 10.1016/j.annonc.2026.10.1281. Epub ahead of print. PMID: 42927856.

Tags: CTLA-4, Hematology/Oncology, HIF-2α, immunotherapy, Publications, renal-cell carcinoma, VEGFR-TKI

Systemic Mastocytosis With Associated Acute Myeloid Leukemia Identified After Induction Therapy: A Case Report and Literature Review

Han J, Ghamsari F, Yan J, Kim P. Systemic Mastocytosis With Associated Acute Myeloid Leukemia Identified After Induction Therapy: A Case Report and Literature Review.[...]

Asia-Pacific Transplant Oncology Symposium 2024: Expert Statements on the Current State and Future Direction of Hepatobiliary Surgical and Transplant Oncology

Law JH, Xie K, Yang J, Kudo M, Muthiah MD, Mehta N, Bhoori S, Pinato DJ, Chee CE, Hatano E, Line PD, Chan SL, Doyle[...]

Osimertinib Plus Platinum-based Chemotherapy in Patients With EGFR-Mutated Advanced NSCLC Post-progression on First-Line Osimertinib: ORCHARD

Goldman JW, Riess JW, Cho BC, Goldberg SB, Le X, Piotrowska Z, Okamoto I, Yu HA, García-Campelo R, de Castro Carpeño J, Ekman S, Reguart[...]